7 Days
Source:
المشهد
Source: المشهد
7 Daysالمشهد
Source: المشهد
7 DaysReady to play
Ready to play
A study has found that sotagliflozin may offer cardiovascular benefits beyond blood sugar control, by limiting the overactivation and clumping of platelets—a mechanism that could reduce the formation of blood clots, heart attacks, and strokes. In experiments in mice, the drug reduced clot formation by about 60%, compared with 5% to 10% for empagliflozin. But these findings do not make it a “miracle drug”: researchers plan to continue evaluating its effects in patients with different health conditions.
Notice: This Is an AI-Generated Summary
Comments (0)